Company news

Elixiron Immunotherapeutics (cayman) Limited (TPEX:7871) news

Elixiron Immunotherapeutics (cayman) Limited news releases on 6ix. Latest, Jun 10, 2026: Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results…

View Elixiron Immunotherapeutics (cayman) Limited →

Press releases & updates

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

June 9, 2026